TACSTD2 and neoplasm: Sacituzumab govitecan (Trodelvy) is a Trop-2-directed antibody and topoisomerase inhibitor conjugate drug that targets the Trop-2 antigen, expressed on various tumor cells, and delivers 7-ethyl-10-hydroxycamptothecin (SN-38; a topoisomerase I inhibitor), which causes single strand breaks, inducing DNA damage and apoptosis.